Role of insulin resistance in kidney dysfunction: Insights into the mechanism and epidemiological evidence

Nephrology Dialysis Transplantation

Volumn 28, Issue 1, 2013, Pages 29-36

  De Cosmo, S ^a   Menzaghi, C ^a   Prudente, S ^a   Trischitta, V ^a,b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

diabetic kidney disease; genetic susceptibility; insulin sensitizers; insulin signalling; metabolic syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ALBUMIN; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; I KAPPA B KINASE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN SENSITIZING AGENT; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE C; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALBUMINURIA; BLOOD VESSEL PERMEABILITY; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; GENETIC POLYMORPHISM; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; KIDNEY; KIDNEY DISEASES; MICE; PODOCYTES;

EID: 84872221977     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs290     Document Type: Review

References (68)

1. Yoshio N, Hall MD, Patrick J et al. Temporal Trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-2539
2. Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
3. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174
4. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008; 4: 444-452
5. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005; 1: 100-110
6. Ferrannini E. Effects of insulin on the kidney and the cardiovascular system. In: Mogensen CE (ed). The Kidney and Hypertension in Diabetes Mellitus. 4th ed. Boston: Kluwer Academic Publishers, 1998, pp. 131-140
7. Trevisan R, Bruttomesso D, Vedovato M et al. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes 1998; 47: 1347-1353
8. Vedovato M, Lepore G, Coracina A et al. Effect of sodium intake on blood pressure and albuminuria in type 2 diabetic patients: the role of insulin resistance. Diabetologia 2004; 47: 300-303
9. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55: 1537-1545
10. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917
11. Sharma K, Ramachandrarao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656
12. Jaziri R, Aubert R, Roussel R et al. Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes. Nephrol Dial Transplant 2010; 25: 2231-2237
13. Komaba H, Igaki N, Goto S et al. Increased serum high-molecularweight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 2006; 26: 476-482
14. Looker HC, Krakoff J, Funahashi T et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4010-4017
15. Menzaghi C, De Cosmo S, Copetti M et al. Relationship between ADIPOQ gene, circulating high molecular weight adiponectin and albuminuria in individuals with normal kidney function: evidence from a family-based study. Diabetologia 2011; 54: 812-818
16. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
17. Ohashi K, Iwatani H, Kihar a S et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectinknockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 1910-1917
18. Cusi K, Maezono K, Osman A et al. Insulin resistance differentially affects the PI3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-320
19. Prudente S, Morini E, Trischitta V. Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol 2009; 5: 682-693
20. Formoso G, Di Tomo P, Andreozzi F et al. The TRIB3 R84 variant is associated with increased carotid intima-media thickness in vivo and with enhanced MAPK signalling in human endothelial cells. Cardiovasc Res 2011; 89: 184-192
21. Jaureguia A, Mintzb DH, Mundela P et al. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens 2009; 18: 539-545
22. Coward RJ, Welsh GI, Yang J et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54: 3095-3102
23. Welsh GI, Hale LJ, Eremina Vet al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010; 12: 329-340
24. Catalano C, Muscelli E, Quinones Galvan A et al. Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes 1997; 46: 868-875
25. Coward RJ, Welsh GI, Koziell A et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes 2007; 56: 1127-1135
26. Doublier S, Salvidio G, Lupia E et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030
27. Kamijo-Ikemori A, Sugaya Y, Yasuda T. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011; 34: 691-696
28. Mima A, Ohshiro Y, Kitada M et al. Glomerular-specific protein kinase C-b-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int 2011; 79: 883-896
29. Mykkanen L, Zaccaro DJ, Wagenknecht LE et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800
30. Kurella M, Lo JC, Chertow GM. Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults. J Am Soc Nephrol 2005; 16: 2134-2140
31. Thomas G, Sehgal AR, Kashyap SR et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6: 2364-2373
32. Yip J, Mattock MB, Morocutti A et al. Insulin resistance in insulindependent diabetic patients with microalbuminuria. Lancet 1993; 342: 883-887
33. Ekstrand AV, Groop PH, Gronhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant 1998; 13: 3079-3083
34. Orchard T, Chang Y-F, Ferrell RE et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Kidney Int 2000; 62: 963-970
35. Thorn LM, Forsblom C, Fagerudd J. Metabolic Syndrome in Type 1 Diabetes. Diabetes Care 2005; 28: 2019-2024
36. De Cosmo S, Bacci S, Piras GP et al. High prevalence of risk factor for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia 1997; 40: 1191-1196
37. Groop L, Ekstrand A, Forsblom C et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulindependent) diabetes mellitus. Diabetologia 1993; 36: 642-647
38. De Cosmo S, Minenna A, Ludovico O et al. Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association. Diabetes Care 2005; 28: 910-915
39. De Cosmo S, Trevisan R, Minenna A et al. Insulin resistance and the cluster of abnormalities related to the metabolic syndrome are associated with reduced glomerular filtration rate in patients with type 2. Diabetes Care 2006; 29: 432-434
40. Doria A. Genetics of diabetes complications. Curr Diab Rep 2010; 10: 467-475
41. De Cosmo S, Argiolas A, Miscio G et al. A PC-1 aminoacid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria. Diabetes 2000; 49: 521-524
42. Canani LH, Ng DP, Smiles A et al. Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes. Diabetes 2002; 51: 1188-1193
43. De Cosmo S, Minenna A, Zhang YY et al. Association of the qant of ENPP1 gene with decreased kidney function among121vari patients with type 2 diabetes. Am J Kidney Dis 2009; 53: 273-280
44. Jacobsen P, Grarup N, Tarnow L et al. PC-1 amino acid variant (K121Q) has no impact on progression of diabetic nephropathy in type 1 diabetic patients. Nephrol Dial Transplant 2002; 17: 1408-1412
45. Rasmussen SK, Urhammer SA, Pizzuti A et al. The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. Diabetes 2000; 49: 1608-1611
46. Bacci S, Rizza S, Prudente S et al. The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. Diabetes 2011; 60: 1000-1007
47. Bacci S, Di Paola R, Menzaghi C et al. ENPP1 Q121 variant, increased pulse pressure and reduced insulin signaling, and nitric oxide synthase activity in endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29: 1678-1683
48. Almind K, Inoue G, Pedersen O et al. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling.: Evidence from transfection studies. J Clin Invest 1996; 97: 2569-2575
49. Marini MA, Frontoni S, Mineo D et al. The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 3368-3371
50. Almind K, Bjørbaek C, Vestergaard H et al. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 1993; 342: 828-832
51. Morini E, Prudente S, Succurro E et al. IRS1 G972R polymorphism and type 2 diabetes: a paradigm for the difficult ascertainment of the contribution to disease susceptibility of 'low-frequency-low-risk' variants. Diabetologia 2009; 52: 1852-1857
52. Thameem F, Puppala S, Schneider J et al. The Gly(972)Arg Variant of Human Insulin Receptor Substrate 1 Gene Is Associated With Variation in Glomerular Filtration Rate Likely Through Impaired Insulin Receptor Signaling. Diabetes. 2012 [Epub ahead of print May 22], DOI: 10.2337/db11-1078
53. Voight BF, Scott LJ, Steinthorsdottir V et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579-589
54. Herrmann SM, Ringel J, Wang JG et al. Study Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin diabetes mellitus (BeDiaM) study. Diabetes 2002; 51: 2653-2657
55. Caramori ML, Canani LH, Costa LA et al. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2002; 52: 3010-3013
56. De Cosmo S, Motterlini N, Prudente S et al. Impact of the PPARgamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 2009; 58: 2920-2929
57. De Cosmo S, Prudente S, Lamacchia O. et al. PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrol Dial Transplant 2011; 26: 4011-4016
58. Kottgen A, Glazer NL, Dehghan A et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009; 41: 712-717
59. Pezzolesi MG, Poznik GD, Mychaleckyj JC et al. Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 2009; 58: 1403-1410
60. Hanson RL, Craig DW, Millis MP et al. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 2007; 56: 975-983
61. Drawz PE, Sedor JR. The genetics of common kidney disease: a pathway toward clinical relevance. Nat Rev Nephrol 2011; 7: 458-468
62. Dupuis J, Langenberg C, Prokopenko I. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42: 105-116
63. Kraja AT, Vaidya D, Pankow JS et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes 2011; 60: 1329-1339
64. Miyazaki1 Y, Cersosimo1 E, Triplitt C et al. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney International 2007; 72: 1367-1373
65. Sarafidis PA, Stafylas PC, Georgianos PI et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 2010; 55: 835-847
66. Lachin JM, Viberti G, Zinman B et al. ADOPT Study Group. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 2011; 6: 1032-1040
67. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006; 70: 1223-1233
68. Morales E, Praga M. The effect of weight loss in obesity and chronic kidney disease. Curr Hypertens Rep 2012; 14: 170-176